Checkmate Pharmaceuticals (CMPI) executive Chaudhary received 27,300 Stock Option (Right to Buy)

Insider transactions reported

Kleem Chaudhary (executive at Checkmate Pharmaceuticals Inc., CMPI) reported that they received 27,300 Stock Option (Right to Buy) on Aug 4, 2021.

Reporting person

Chaudhary Kleem

Options and other derivatives

Holdings before and after

• Stock Option (Right to Buy): 0 to 27,300 direct

Footnotes from the filing

1. 1. 25% of the shares subject to such option vest and become exercisable on August 4, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ